Why AbbVie Stock Jumped Today
Shares of AbbVie (NYSE: ABBV) climbed on Monday after the pharmaceutical giant struck a deal to acquire clinical-stage biotech Apogee Therapeutics (NASDAQ: APGE) for $10.9 billion.
Image source: The Motley Fool.
Under the terms of the deal, AbbVie would purchase Apogee for $135.11 per share in cash. That's a 49% premium over the stock's closing price on Thursday, the last trading day before the deal's announcement.
Source Fool.com
AbbVie Inc. Stock
€215.40
-1.010%
The stock is an absolute favorite of our community with 45 Buy predictions and no Sell predictions.
As a result the target price of 230 € shows a slightly positive potential of 6.78% compared to the current price of 215.4 € for AbbVie Inc..
